

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Eptinezumab for preventing migraine ID3803

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Lundbeck (eptinezumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Brain and Spine Foundation • Brain Charity • Migraine Action • Migraine Trust • National Migraine Centre • Neurological Alliance • OUCH UK • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association for the Study of Headache • British Geriatrics Society • British Neuropathological Society • British Pain Society • Institute of Neurology • Migraine in Primary Care Advisors • Neuromodulation Society of UK and Ireland • Physiotherapy Pain Association • Primary Care Neurology Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (amitriptyline, propranolol, topiramate) • Allergan (botulinum toxin type A) • Aurobindo Pharma (propranolol, topiramate) • Brown & Burk UK (amitriptyline) • Eli Lilly (galcanezumab) • Flamingo Pharma UK (amitriptyline) • Galderma (botulinum toxin type A) • Glenmark Pharmaceuticals (topiramate) • Janssen-Cilag (topiramate) • Merz Pharma (botulinum toxin type A) • Novartis (erenumab)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Camden CCG • NHS Castle Point and Rochford CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Pharmanovia (propranolol) • Rosemont Pharmaceuticals (amitriptyline, propranolol, topiramate) • Sandoz (propranolol) • Teva UK (fremanezumab) • Thame Laboratories (amitriptyline, propranolol) • Tillomed Laboratories (propranolol) • Viatrix (topiramate) • Wockhardt UK (amitriptyline) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Neurological Research Trust • Cochrane Pain, Palliative Care and Supportive Care Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • Pain Relief Foundation <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts

¹ Non company consultees are invited to submit statements relevant to the group they are representing.